A bit of a lackluster effort today. I suspect this one is still flying under the radar for most punters and we'll have to be patient until further announcements are released to the market.
Will the next announcement be:
A further update on material increases for USCOM 1A orders in China?; or
Something to do with orders in US or Europe?; or
Another surprise from out of left field again?
As for future SP, I'll go out on a limb here and here's my optimistic take. If USCOM delivers and the sales keep rolling in and the new device approvals come in 2H, I reckon we could see multiple spikes for the rest of this year setting new SP highs. Further out to 2021 maybe a new trading range between $1 - $3. (MC of $150mil - $450 million) In 2022, looking at SP of $3 + (MC of $450 million plus) … IMHO.
The company is in the box seat, with sales rolling in and with NO debt. Rob (The Professor) did mention in the NWR presentation the organic company growth over the last 6 years has been 358% and the plan is to significantly accelerate that growth over the next 5 years.
USCOM have the right medical devices and tech at the right time. In the meantime we wait...
GLTAH
Add to My Watchlist
What is My Watchlist?
